EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CRISPR‐Engineered CAR‐T Cell Therapy for Epstein–Barr Virus‐Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects

Noor Allehyani iD, Mohammed Alissa iD, Abdullah Alghamdi iD, Mohammed A Alshehri iD, Ghadah S Abusalim iD, Alaa S Alhegaili iD, Tawfiq N Juraybi iD, Meshari A Alsuwat iD

Reviews in Medical Virology · 2026

DOI: 10.1002/rmv.70199 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, 2026. Verfasst von Noor Allehyani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Herpesvirus 4, Human, Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Prince Sattam bin Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein‐Barr virus (EBV)‐associated nasopharyngeal carcinoma (NPC) remains a clinically challenging malignancy, particularly in recurrent or metastatic disease where durable responses to chemoradiotherapy and immune checkpoint blockade are limited. The viral aetiology of NPC provides a strong biological rationale for immune‐based treatment; however, translation of chimaeric antigen receptor (CAR) T‐cell therapy into this solid tumour setting is constrained by poor tumour trafficking, antigen heterogeneity, limited surface accessibility of EBV latent antigens, T‐cell exhaustion, and an immunosuppressive tumour microenvironment. This review critically evaluates the emerging therapeutic prospects of CRISPR‐engineered CAR‐T cell therapy for EBV‐associated NPC. It synthesises evidence on EBV latency biology, NPC immune evasion, solid‐tumour CAR‐T limitations, and genome‐engineering strategies including conventional CRISPR‐Cas9, base editing, prime editing, and double‐strand‐break‐sparing targeted integration. Particular attention is given to genotoxicity, chromosomal rearrangements, chromosome loss, bystander and off‐target editing, manufacturing heterogeneity, and the regulatory and biological barriers that currently separate technical feasibility from NPC‐specific clinical implementation. Available clinical evidence from checkpoint blockade, EBV‐specific adoptive T‐cell therapy, base‐edited CAR‐T cells in haematologic malignancy, and early CRISPR‐edited T‐cell trials supports the feasibility of immune and genetic redirection but does not establish efficacy of a clinically validated CRISPR‐engineered CAR‐T platform for NPC. Future development should prioritise surface‐accessible antigen validation, fit‐for‐purpose selection of editing technology, genomic safety, scalable manufacturing, and biomarker‐driven early‐phase trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveHerpesvirus 4, HumanNasopharyngeal CarcinomaEpstein-Barr Virus InfectionsCRISPR-Cas SystemsReceptors, Chimeric AntigenNasopharyngeal NeoplasmsHumansGene EditingTumor Microenvironment

Stichwörter der Autor:innen

CAR‐T cell therapyCRISPR‐Cas9adoptive cellular therapyepstein‐barr virusnasopharyngeal carcinomatumour microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
  • Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
  • Department of Basic Sciences, College of Nursing, Taif University, Taif, Saudi Arabia.

ORCID-Profile: Noor Allehyani, Mohammed Alissa, Abdullah Alghamdi, Mohammed A Alshehri, Ghadah S Abusalim, Alaa S Alhegaili, Tawfiq N Juraybi, Meshari A Alsuwat

Förderung

  • Prince Sattam bin Abdulaziz University

Zitieren

APA

Allehyani, N., Alissa, M., Alghamdi, A., Alshehri, M. A., Abusalim, G. S., Alhegaili, A. S., Juraybi, T. N., & Alsuwat, M. A. (2026). CRISPR‐Engineered CAR‐T Cell Therapy for Epstein–Barr Virus‐Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70199

Vancouver

Allehyani N, Alissa M, Alghamdi A, Alshehri MA, Abusalim GS, Alhegaili AS, et al. CRISPR‐Engineered CAR‐T Cell Therapy for Epstein–Barr Virus‐Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70199

BibTeX
@article{Allehyani2026,
  author = {Allehyani, Noor and Alissa, Mohammed and Alghamdi, Abdullah and Alshehri, Mohammed A and Abusalim, Ghadah S and Alhegaili, Alaa S and Juraybi, Tawfiq N and Alsuwat, Meshari A},
  title = {CRISPR‐Engineered CAR‐T Cell Therapy for Epstein–Barr Virus‐Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects},
  journal = {Reviews in Medical Virology},
  year = {2026},
  doi = {10.1002/rmv.70199}
}
Kostenlos starten →